leadf
logo-loader
viewNemaura Medical Inc

Nemaura launches sugarBEAT app on Google’s Play Store ahead of BEAT diabetes subscription service

The launch of the sugarBEAT app is a big step towards the UK-based medtech company’s commercial milestones

Nemaura Medical Inc - Nemaura launches sugarBEAT app on Google’s Play Store ahead of BEAT diabetes subscription service
The sugarBEAT app on Google's Play Store includes time-in-range profiling features which are rapidly being adopted as the primary metric for managing individual daily blood glucose profiles

Nemaura Medical Inc (NASDAQ:NMRD), the maker of the sugarBEAT continuous glucose monitor, said Tuesday that it has launched its sugarBEAT app for Android devices on the Play Store to prep for the launch of the company’s BEAT diabetes subscription-based service expected next month. 

"We believe that the launch of our app is a big step towards our commercial milestones, and we are looking forward to launching the BEAT diabetes subscription service shortly during Type 2 Diabetes Prevention Week in the UK. This is a very exciting time in our company’s development,” said Nemaura CEO Faz Chowdhury in a statement.

“The sugarBEAT app includes time-in-range profiling features which we believe is rapidly being adopted as the primary metric for managing individual daily blood glucose profiles," he added.

READ: Nemaura’s exciting 2Q sets it up to execute commercial strategy for sugarBEAT

The digital health offering, BEAT diabetes, help patients with prediabetes and Type 2 diabetes by empowering them with tools to better manage, prevent and potentially even reverse their condition. The digital health offering is a subscription-based service.

The full range of subscription-based services includes an app that makes lifestyle recommendations based on blood glucose levels, offers one-on-one coaching and routinely measures other parameters that allow improved disease management.

Both BEAT diabetes and the sugarBEAT monitor itself serve the underserved $69 billion market for Type 2 diabetics and $50 billion market for pre-diabetics.

The Loughborough, UK-based medtech company launched shipments of its sugarBEAT, the world’s first painless glucose monitor, to patients in August 2019 in the UK. The wave of shipments was Nemaura’s first foray into the European market after receiving its CE mark, an EU seal of approval, in May 2019.

“The UK licensee of SugarBEAT, DB Ethitronix, is currently in the process finalizing the launch of online sales of sugarBEAT,” said the company.

Nemaura is planning to initiate a user study comparing its sugarBEAT continuous glucose monitor (CGM) directly against a highly successful major incumbent CGM sensor.  The company’s goal with the study is to position sugarBEAT as a non-invasive, daily/flexible, cost-effective alternative to traditional, expensive invasive CGMs.

sugarBEAT consists of a daily disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings every five minutes for up to 24 hours. The genius of SugarBEAT lies in its skin-patch technology which allows for better glucose management.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive 

Quick facts: Nemaura Medical Inc

Price: 3.75 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $85.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Nomad Royalty has ambitions of becoming next 'large tier mining royalty company'

Proactive Research analyst Ryan Long says Nomad Royalty Company Ltd (TSE:NSR) has a diversified portfolio of large cash flow and near-term cash flow generating mining assets. He says around 50% of its NAV currently comes from cash flow generating assets and that's expected to increase to 85% in...

1 hour, 35 minutes ago

2 min read